A second molecule, APG101, which consists of the extracellular domain of Fas fused to the Fc domain of IgG binds FasL, thereby acting as an antagonist, is in a phase II clinical trial for glioblastoma treatment [120,121]. The gene discussed is FAS; the disease is glioblastoma.